A phase II study published in the Journal of Clinical Oncology reports that patients with inoperable, locally advanced non-small cell lung cancer (NSCLC) who are ineligible for concurrent chemoradiotherapy may benefit from a chemotherapy-free regimen of durvalumab and radiation. The DART trial achieved a 2-year progression-free survival rate of 39%, surpassing the 20% historical benchmark for sequential chemoradiotherapy.
Bridging the Treatment Gap for Frail Patients
For fit patients with inoperable, locally advanced NSCLC, the standard treatment approach is concurrent platinum-based chemotherapy and radiation, followed by consolidation with durvalumab. However, this intensive approach is often too toxic for older patients or those with significant comorbidities. According to the DART study data, this “chemotherapy-ineligible” population has historically lacked a universally accepted standard of care, often leaving them with few effective options.
Did you know?
The median age of participants in the DART trial was 82 years, highlighting a focus on a demographic frequently excluded from more aggressive clinical studies.
Trial Design and Clinical Outcomes
The DART trial was a multicenter, single-arm, prospective phase II study that enrolled 58 patients. Participants received conventionally fractionated radiation therapy alongside 1,500 mg of durvalumab every four weeks, continuing for up to 12 months. The study aimed to test whether integrating immunotherapy directly with radiation could improve outcomes without the added burden of systemic chemotherapy.
The results, as published in the Journal of Clinical Oncology (doi:10.1200/JCO-25-02517), showed:
- 2-Year Progression-Free Survival (PFS): 39%, exceeding the 36% target and the 20% historical benchmark.
- 2-Year Overall Survival (OS): 54%.
Researchers noted that performance status and PD-L1 expression remained critical indicators of success. Patients with better ECOG performance status saw improved PFS and OS, while PD-L1-positive tumors correlated with better cancer-specific survival.
Managing Toxicity and Safety Risks
While the efficacy data is encouraging, the safety profile necessitates caution. The study reported that 21% of patients experienced grade 3 or 4 treatment-related adverse events. More significantly, 7% of participants experienced grade 5 (fatal) adverse events, including cases of cardiac arrest and radiation pneumonitis.
Pro Tip:
Because 31% of patients in the DART study discontinued durvalumab early due to adverse events, clinicians are advised to prioritize strict patient selection and multidisciplinary oversight when considering this regimen for frail patients.
Future Directions in NSCLC Care
The DART trial provides a prospective look at a potential shift in how we treat patients who cannot tolerate the standard-of-care, platinum-based concurrent chemoradiotherapy. While these findings do not yet establish a new standard of care due to the single-arm nature of the trial, they offer a foundation for future research. The next phase for oncology teams involves identifying how best to identify patients who are likely to benefit while minimizing the risk of severe toxicities like pneumonitis.
Frequently Asked Questions
What is the DART trial?
DART is a phase II clinical trial investigating the use of durvalumab combined with radiation therapy in NSCLC patients who are too frail or have too many comorbidities to undergo standard concurrent chemoradiotherapy.
Is this treatment now the standard of care?
No. While the results were encouraging, the study was single-arm and used historical controls. Further validation is required before this approach becomes a universally accepted standard.
What were the most common serious side effects?
The study reported grade 3 or 4 adverse events in 21% of patients, with a 7% rate of grade 5 (fatal) events, including radiation pneumonitis and cardiac arrest.
Have you encountered challenges in treating elderly NSCLC patients with limited chemotherapy options? Share your thoughts in the comments or subscribe to our newsletter for the latest updates on clinical oncology research.
Worth a look